2020 Pediatric Rheumatology Symposium

April 29-May 2, 2020

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

View by Number View by Title View Sessions

View by Date

Abstract Number: 151

Differences in Chromatin Architecture Between Treatment-Naïve Pediatric and Adult Lupus Patients
Abstract Number: 152

Hemophagocytic Lymphohistiocytosis (HLH) Genetic Variants in Childhood-onset SLE (cSLE) with Macrophage Activation Syndrome (MAS)
Abstract Number: 153

Double Negative T Cells in Juvenile Dermatomyositis
Abstract Number: 154

T Helper Cell Differentiation in Polyarticular Juvenile Idiopathic Arthritis
Abstract Number: 155

Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) Is Characterized by a Novel Subset of Monocytes with Markers Associated with Crossing the Blood Brain Barrier (BBB)
Abstract Number: 156

Metabolic Profiling in Juvenile Dermatomyositis
Abstract Number: 157

Chondrocytes Influence Fibroblast-like Synoviocytes from Patients with Juvenile Idiopathic Arthritis, Through the Abrogation of BMP Signaling, to Delay Cell Differentiation and Maturation
Abstract Number: 158

Genetics of Age at Diagnosis in Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 159

Interleukin-18 as a Key Cytokine to Understand Pathology and to Decide Appropriate Therapeutic Strategy in Chronic Arthritic Systemic Juvenile Idiopathic Arthritis
Abstract Number: 160

CD3 Downregulation on T-cells Is Concomitant with Arginase Upregulation on Myeloid Cells in Synovial Fluid of Patients with Juvenile Idiopathic Arthritis
Abstract Number: 161

Impact of the Month of Birth on the Development of Juvenile Idiopathic Arthritis in the United States
Abstract Number: 162

Minor Biomarkers in Juvenile Idiopathic Arthritis (JIA)
Abstract Number: 163

Anti-Dense Fine Speckled (DFS) Autoantibodies in Autoinflammatory Vasculopathies
Abstract Number: 164

The Juvenile Idiopathic Arthritis-Associated IL2RA and IL6R Haplotypes Contain Enhancers Whose Functions Are Altered by JIA-Associated Genetic Variants
Abstract Number: 165

A Massively Parallel Reporter Assay Screen of Genetic Variants on JIA Haplotypes Reveals Variants Associated with Altered Function of an Intergenic Enhancer in the HLA Class II Locus

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].